Byondis Announces First Patient Dosed in Phase 1 Clinical Trial of Novel SIRPα-Directed Monoclonal Antibody BYON4228 in Patients With Advanced or Metastatic Solid TumorsContributed by: Business WireLogoImagesLouis Denis, MD, Chief Medical Officer, ByondisTagsScienceBiotechnologyResearchPharmaceuticalOncologyGeneral HealthHealthClinical TrialsByondis B.V.